here's a quick summary of the 7 trials and their estimated completion dates, in order of completion date (earliest first), using the clinical trials website data as the guide. apologies for formatting, HC snuffed it all....
Note that 6 of the 7 trials are expected to complete this year.
HER-Vaxx(Herizon)
NCT02795988
Active, notrecruiting
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Last Update: March 2, 2023
Actual Start Date: August 30, 2017
Estimated Primary Completion: January 2024
Estimated Study Completion: February 2024
Link: https://classic.clinicaltrials.gov/ct2/show/NCT02795988?term=NCT02795988&draw=2&rank=1
HER-Vaxx(next HERIZON)
NCT05311176
Active, notrecruiting
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) (nextHERIZON)
Last Update: February 29, 2024
Actual Start Date: August 17, 2022
Estimated Primary Completion: March 31, 2024
Estimated Study Completion: July 1, 2026
Link: https://classic.clinicaltrials.gov/ct2/show/NCT05311176?term=imugene&draw=2&rank=4
azer-cel
NCT03666000
Recruiting
Dose-escalation, Dose-expansionStudy of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
Last Update: November 18, 2023
Actual Start Date: March 11, 2019
Estimated Primary Completion: March 2024
Estimated Study Completion: June 2024
Link: https://classic.clinicaltrials.gov/ct2/show/NCT03666000?term=imugene&draw=2&rank=1
CHECKvacc
NCT05081492
Active, notrecruiting
CF33-hNIS-antiPDL1 for theTreatment of Metastatic Triple Negative Breast Cancer
Last Update: January 5, 2024
Actual Start Date: October 18, 2021
Estimated Primary Completion: September 22, 2024
Estimated Study Completion: September 22, 2024
Link: https://classic.clinicaltrials.gov/ct2/show/NCT05081492?term=imugene&draw=2&rank=7
onCARlytics(OASIS)
NCT06063317
Recruiting
A Study of onCARlytics (CF33-CD19)in Combination With Blinatumomab in Adults With Advanced or Metastatic SolidTumors (OASIS) (OASIS)
Last Update: January 12, 2024
Actual Start Date: October 2, 2023
Estimated Primary Completion: September 2024
Estimated Study Completion: September 2024
Link: https://classic.clinicaltrials.gov/ct2/show/NCT06063317?term=imugene&draw=2&rank=2
Vaxinia(CF33-hnis), (MAST)
NCT05346484
Recruiting
A Study of CF33-hNIS (VAXINIA), anOncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in AdultsWith Metastatic or Advanced Solid Tumors (MAST)
Last Update: January 11, 2024
Actual Start Date: May 17, 2022
Estimated Primary Completion: December 2024
Estimated Study Completion: January 2025
Link: https://classic.clinicaltrials.gov/ct2/show/NCT05346484?term=imugene&draw=2&rank=3
PD1-Vaxx(Imprinter)
NCT04432207
Active, notrecruiting
A Study of IMU-201 (PD1-Vaxx), aB-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
Last Update: January 25, 2024
Actual Start Date: November 30, 2020
Estimated Primary Completion: February 2026
Estimated Study Completion: March 2026
Link: https://classic.clinicaltrials.gov/ct2/show/NCT04432207?term=imugene&draw=2&rank=5
(20min delay)
